Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.31 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2474035 | 1.00 | OPRL1 (0.34) | OPRL1OPRM1NOS3NOS1NOS2 | |
| SCHEMBL2470559 | 0.81 | NOS3 (0.36) | OPRL1OPRM1NOS3NOS1NOS2 | |
| SCHEMBL2470462 | 0.81 | NOS3 (0.36) | OPRL1OPRM1NOS3NOS1NOS2 | |
| SCHEMBL2476492 | 0.81 | NOS3 (0.36) | OPRL1OPRM1NOS3NOS1NOS2 | |
| SCHEMBL26511990 | 0.78 | OPRL1 (0.39) | OPRL1OPRM1NOS3NOS1NOS2 | |
| SCHEMBL2473501 | 0.77 | OPRL1 (0.34) | OPRL1OPRM1NOS3NOS1NOS2 | |
| SCHEMBL2477395 | 0.77 | OPRL1 (0.40) | OPRL1OPRM1NOS3NOS1NOS2 | |
| SCHEMBL2474725 | 0.77 | OPRL1 (0.40) | OPRL1OPRM1NOS3NOS1NOS2 | |
| SCHEMBL30586977 | 0.77 | OPRL1 (0.43) | OPRL1OPRM1NOS3NOS1NOS2 | |
| SCHEMBL2472323 | 0.77 | OPRL1 (0.43) | OPRL1OPRM1NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2664617-A1 | Method of making a 2,6-diaryl piperidine derivative | Genzyme Corporation (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2374804-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | Genzyme Corporation (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7550484-B2 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | GENZYME CORPORATION (US) | 2009-06-23 | — | — | US | disclosed |
| US-7501518-B2 | Methods of making 2,6-diaryl piperidine derivatives | GENZYME CORPORATION (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1809613-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006049764-A2 | METHODS OF MAKING 2,6-DIARYL PIPERIDINE DERIVATIVES | ANORMED INC. (CA) | 2006-05-11 | — | — | WO | disclosed |
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ANORMED CORPORATION (CA) | 2005-07-14 | — | — | US | disclosed |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | ANORMED CORPORATION (CA) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154201-A1 | Methods of making 2,6-diaryl piperidine derivatives | ALDH7A1, DPYD, ALDH1A1 | OPRL1 1945/4885OPRM1 1807/4885NOS3 2111/4885 |
| US-20050059702-A1 | Chemokine receptor binding heterocyclic compounds with enhanced efficacy | CXCR4, CXCR1, CCR5 | OPRL1 101/4885OPRM1 216/4885NOS3 3770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.